Navigation Links
ISTA Pharmaceuticals' New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration
Date:1/15/2009

rand name TALION(R). TALION was co-developed by Tanabe Seiyaku and Ube Industries, Ltd., who discovered bepotastine. In 2001, Tanabe Seiyaku granted Senju Pharmaceutical Co., Ltd., exclusive worldwide rights, with the exception of certain Asian countries, to develop, manufacture and market bepotastine for ophthalmic use. In 2006, ISTA licensed the exclusive North American rights from Senju to an eye drop formulation of bepotastine for the treatment of allergic conjunctivitis.

About ISTA Pharmaceuticals

ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA's products and product candidates addressing the $4.7 billion U.S. prescription ophthalmic industry include therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. The Company currently markets three products and is developing a strong product pipeline to fuel future growth and market share, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at http://www.istavision.com.

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements. Without limiting the foregoing, but by way of example, statements contained in this press release related to the FDA's timely review and approval of Bepreve, ISTA's belief the FDA will review and take action on Bepreve within ten months of filing and ISTA's expectation of becoming the leading niche ophthalmic pharmaceutical company are forward-looking statements. Except as required by law, ISTA disclaims any intent or obligation to update any forward-looking statements. These forward-looking statements are based on ISTA's expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual resul
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... July 28, 2015  For many medical institutions and ... and other inventors can be a constant challenge. Taking ... and successes are rare. A new company ... that. Medical Device Investments (MDI) was created ... hospitals and physicians. MDI develops, manufactures and markets the ...
(Date:7/28/2015)... ALBANY, New York , July 28, 2015 ... of a new report, titled " Cancer Diagnostics ... Forecast, 2014 - 2020 " . According to this ... at a CAGR of 7.6% during the forecast period of ... was valued at US$100,994.5 million and is expected to be ...
(Date:7/28/2015)... , July 28, 2015 The ... with the Canadian Anti-Fraud Centre (CAFC), ... falsely using the CIPA verification seal on illegitimate ... of legitimate online pharmacy member companies who have ... medications to more than 10 million Americans since ...
Breaking Medicine Technology:Medical Device Investments To Become Center Of Excellence For The Commercialization Of Innovative Medical Technologies 2Cancer Diagnostics Market is Expected to Grow at CAGR of 7.6% From 2014 to 2020, to be Worth US$168,649.3 Million by 2020: Transparency Market Research 2Cancer Diagnostics Market is Expected to Grow at CAGR of 7.6% From 2014 to 2020, to be Worth US$168,649.3 Million by 2020: Transparency Market Research 3Cancer Diagnostics Market is Expected to Grow at CAGR of 7.6% From 2014 to 2020, to be Worth US$168,649.3 Million by 2020: Transparency Market Research 4Canadian International Pharmacy Association (CIPA) Continues to Fight Rogues Fraudulently Using the Trusted CIPA Verification Seal 2Canadian International Pharmacy Association (CIPA) Continues to Fight Rogues Fraudulently Using the Trusted CIPA Verification Seal 3
(Date:7/29/2015)... ... July 29, 2015 , ... ... entered into a partnership with 247Ergo, an ergonomics specialty firm. Purpose of the ... projects that the companies undertake could improve worker mobility, functionality and fitness levels. ...
(Date:7/29/2015)... Estates, IL (PRWEB) , ... July 29, 2015 , ... ... both benefit from two new products on Mercola.com: a vertical “garden tower” and enhanced ... which can be squeezed into small corners on a porch, balcony, or rooftop – ...
(Date:7/29/2015)... ... 29, 2015 , ... Indiana is known for basketball, the boyhood home of ... Indianapolis, which plans to expand across the state. , Ray Kennedy, owner of the ... in business and we should double our first year’s revenue. More importantly, we ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... seeking funding for a study on the potentially lifesaving impact of removing aluminum ... . , The research proposal is based on a successful pilot study ...
(Date:7/29/2015)... ... July 29, 2015 , ... Elizabeth ... in Sarasota to be chosen by the manufacturer to offer and perform ... injectable, non-invasive way to treat and eliminate double chin fat,” Dr. Callahan explained. ...
Breaking Medicine News(10 mins):Health News:HealthPostures and 247Ergo Partnership Strengthens America's Wellness 2Health News:HealthPostures and 247Ergo Partnership Strengthens America's Wellness 3Health News:Mercola.com Introduces NEW Garden Tower and Enhanced Mineral Solution for Healthy Plants 2Health News:Zerorez® Announces Plans to Roll Across Indiana—“The Crossroads of America.” 2Health News:Zerorez® Announces Plans to Roll Across Indiana—“The Crossroads of America.” 3Health News:Children's Medical Safety Research Institute Announces Innovative Study on Alzheimer’s Treatment Is Subject of Crowd Funding Campaign 2Health News:Children's Medical Safety Research Institute Announces Innovative Study on Alzheimer’s Treatment Is Subject of Crowd Funding Campaign 3Health News:SkinSmart Dermatology is First in Sarasota to Offer Kybella Treatments to Reduce Double Chin Fat 2Health News:SkinSmart Dermatology is First in Sarasota to Offer Kybella Treatments to Reduce Double Chin Fat 3
... was diagnosed with lung cancer has won $ 1 million in ... suffering from an inoperable lung cancer. ,Doctors have given ... At this juncture, he has won this lottery. But the irony ... paid $50,000 in annual installments over twenty years. ,Schenk ...
... University in Chicago claim that men who have undergone ... type// of dementia. This study was published in Cognitive ... on 106 men. Out of this, 25 developed a ... undergone vasectomy. According to the chief scientist of this ...
... new study suggests that patients who develop Parkinson's ... history includes alcohol// abuse may be more likely ... of medications used to treat their condition. ... hypersexuality, binge eating and pathological gambling—have been associated ...
... People who have multiple sclerosis (MS) for 10 years and have ... they// have “benign MS” and that their symptoms will likely not ... A new study shows that unfortunately this may not be correct. ... nearly half of those whose MS was benign at 10 years, ...
... Medicare coverage for colorectal cancer screening has increased, there ... a report published recently, some of these disparities are ... ,Colorectal cancer is the third most common ... with approximately 145,290 new cases in 2005, according to ...
... test that can distinguish between a pair of nearly ... treatment. ,Their report is published this week ... the National Academy of Sciences. ,"This simple ... quickly implemented in the clinic to benefit patients by ...
Cached Medicine News:Health News:Compulsive Gambling Linked to Parkinson's Disease Medications 2Health News:Disparities in Colon Cancer Screening Remain Among Medicare Patients 2Health News:A New Two-gene Test to Discern Similar Gastrointestinal Cancers 2
This is adapted to microplate or card....
ScanGel® Incubator...
... The ID-Micro Typing System™ ... for a broad range of ... include antibody screening and identification, ... phenotyping, compatibility testing, reverse serum ...
... 120 Mini-Vertical Gel System simplifies the process of ... format. It is able to run four gels ... To maximize utility and throughput, the 120 mini-vertical ... gels (W x L) at one time. The ...
Medicine Products: